| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|
S86010-5mg |
99.70% | ￥248.00 |
2 | - | - | - |
|
S86010-10mg |
99.70% | ￥390.00 |
5 | - | - | - |
|
S86010-25mg |
99.70% | ￥760.00 |
6 | - | - | - |
|
S86010-50mg |
99.70% | ￥1390.00 |
4 | - | - | - |
|
S86010-100mg |
99.70% | ￥2230.00 |
4 | - | - | - |
|
S86010-200mg |
≥99% | ￥3120.00 |
货期：2-3天 | - | - | - |
|
| 产品描述： | Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | sGC;Guanylatecyclase | ||||||||||||||||||||
| 体外研究： | Riocigua stimulates the recombinant sGC concentration dependently from 0.1 to 100 μM with a two-fold to 73-fold effect by an NO-independent but haem-dependent mechanism. Riociguat inhibits platelet function in washed platelets but not in whole blood, and exerts no direct effects on contractility and relaxation of cardiac myocytes | ||||||||||||||||||||
| 体内研究： | Riociguat (10 mg/kg/d, p.o.) partially reverses the pulmonary arterial hypertension, the right heart hypertrophy and the structural remodelling of the lung vasculature in chronic treatment of hypoxic mice and MCT-injected rats | ||||||||||||||||||||
| 参考文献： | 1. Schermuly RT, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32(4):881-91. 2. Schermuly RT, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011 Apr;20(4):567-76. 3. Donda K, et al. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. PLoS One. 2018 Jul 10;13(7):e0199927. | ||||||||||||||||||||
| 溶解性： | soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京